Akari Therapeutcis (AKTX) Receives Orphan Drug Designation for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Akari Therapeutcis' (NASDAQ: AKTX) treatment of paroxysmal nocturnal hemoglobinuria received FDA orphan drug designation. The generic name is coversin; rEV675.
|Generic Name:||coversin; rEV675|
|Orphan Designation:||Treatment of paroxysmal nocturnal hemoglobinuria|
|Orphan Designation Status:||Designated|
|FDA Orphan Approval Status:||Not FDA Approved for Orphan Indication|
|Marketing Approval Date:||N/A|
|Approved Labeled Indication:|
|Exclusivity End Date:||N/A|
|Sponsor:||Akari Therapeutics Plc|
24 West 40th Street
New York, New York 10018
The sponsor address listed is the last reported by the sponsor to OOPD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Myriad Genetics (MYGN), Sanofi (SNY) Enter Pact for ELIXA Trial Biomarker Analysis
- Finjan Holdings (FNJN) Receives European Patent Related to Adaptive Rule-Based Content Scanners
- KemPharm (KMPH) Files IND with U.S. FDA to Commence Human Trials of KP201/IR
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!